Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 16/20 | 1.00 |
| ▸ | ESR1 | P03372 | 2/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.73 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.73 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.73 |
| ▸ | SHBG | P04278 | 1/20 | 0.73 |
| ▸ | PGR | P06401 | 1/20 | 0.73 |
| ▸ | HTR1A | P08908 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | AR | P10275 | 1/20 | 0.73 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.73 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.73 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.73 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.73 |
| ▸ | PDE4A | P27815 | 1/20 | 0.73 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903619 | 1.00 | STS (1.00) | STSESR1CYP3A4ESR2SLC22A2 | |
| SCHEMBL14515129 | 0.92 | STS (0.85) | STSESR1CYP3A4ESR2SLC22A2 | |
| SCHEMBL31508217 | 0.90 | STS (0.81) | STSESR1CYP3A4ESR2SLC22A2 | |
| SCHEMBL31508390 | 0.89 | STS (0.80) | STSESR1CYP3A4ESR2SLC22A2 | |
| SCHEMBL7778060 | 0.89 | STS (0.88) | STS | |
| SCHEMBL27047066 | 0.88 | STS (0.79) | STSESR1CYP3A4ESR2SLC22A2 | |
| SCHEMBL3051243 | 0.88 | STS (0.84) | STSESR1CYP3A4ESR2SLC22A2 | |
| SCHEMBL13478102 | 0.88 | STS (0.84) | STSESR1CYP3A4ESR2SLC22A2 | |
| SCHEMBL15233086 | 0.88 | STS (0.78) | STSESR1CYP3A4ESR2SLC22A2 | |
| SCHEMBL3051244 | 0.88 | STS (0.84) | STSESR1CYP3A4ESR2SLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102489273-B | Preparation method of magnetic beads of dendritic molecular imprinting polymer on surface of estrogenic nano silica gel | UNIV NANJING MEDICAL | 2013-08-28 | — | — | CN | claimed |
| CN-102169109-B | Method for preparing estrogen substitution template molecular imprinting solid phase micro extraction head | UNIV NANJING MEDICAL | 2013-01-23 | — | — | CN | claimed |
| CN-102489273-A | Preparation method of magnetic beads of dendritic molecular imprinting polymer on surface of estrogenic nano silica gel | UNIV NANJING MEDICAL | 2012-06-13 | — | — | CN | claimed |
| CN-102169109-A | Method for preparing estrogen substitution template molecular imprinting solid phase micro extraction head | UNIV NANJING MEDICAL | 2011-08-31 | — | — | CN | claimed |
| CN-101565485-B | Method for preparing molecularly imprinted polymers of ethinylestradiol analogue | UNIV NANJING MEDICAL | 2011-01-26 | — | — | CN | claimed |
| CN-101565485-A | Method for preparing molecularly imprinted polymers of ethinylestradiol analogue | UNIV NANJING MEDICAL (CN) | 2009-10-28 | — | — | CN | claimed |
| CN-102489273-B | Preparation method of magnetic beads of dendritic molecular imprinting polymer on surface of estrogenic nano silica gel | UNIV NANJING MEDICAL | 2013-08-28 | — | — | CN | disclosed |
| WO-2013102512-A1 | METHOD AND ARRANGEMENT FOR A WATER TREATMENT | SIEMENS AKTIENGESELLSCHAFT (DE) | 2013-07-11 | — | — | WO | disclosed |
| EP-2610221-A1 | Method and arrangement for a water treatment | Siemens Aktiengesellschaft (DE) | 2013-07-03 | — | — | EP | disclosed |
| CN-102169109-B | Method for preparing estrogen substitution template molecular imprinting solid phase micro extraction head | UNIV NANJING MEDICAL | 2013-01-23 | — | — | CN | disclosed |
| CN-102489273-A | Preparation method of magnetic beads of dendritic molecular imprinting polymer on surface of estrogenic nano silica gel | UNIV NANJING MEDICAL | 2012-06-13 | — | — | CN | disclosed |
| CN-102169109-A | Method for preparing estrogen substitution template molecular imprinting solid phase micro extraction head | UNIV NANJING MEDICAL | 2011-08-31 | — | — | CN | disclosed |
| CN-101565485-B | Method for preparing molecularly imprinted polymers of ethinylestradiol analogue | UNIV NANJING MEDICAL | 2011-01-26 | — | — | CN | disclosed |
| CN-101565485-A | Method for preparing molecularly imprinted polymers of ethinylestradiol analogue | UNIV NANJING MEDICAL (CN) | 2009-10-28 | — | — | CN | disclosed |
| US-20080293683-A1 | Hormone Replacement Therapy | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1446128-A1 | USE OF ESTROGENIC COMPOUNDS IN COMBINATION WITH PROGESTOGENIC COMPOUNDS IN HORMONE-REPLACEMENT THERAPY | Pantarhei Bioscience B.V. (NL) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003041718-A1 | USE OF ESTROGENIC COMPOUNDS IN COMBINATION WITH PROGESTOGENIC COMPOUNDS IN HORMONE-REPLACEMENT THERAPY | PANTARHEI BIOSCIENCE B.V. (NL) | 2003-05-22 | — | — | WO | disclosed |
| US-3983112-A | ANTIFERTILITY AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293683-A1 | Hormone Replacement Therapy | ESR2, SHBG, ESRRG | STS 654/4885ESR1 4/4885CYP3A4 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.